13F HOLDINGS REPORT
Omega Fund Management, LLC
Quarter ended Q3 2025 · Filed November 14, 2025 · Accession 0001193125-25-281790
Total Value
$222.4M
Positions
12
Other Managers
0
Confidential Omitted
No
Holdings (12)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Kestra Med Technologies Ltd | BEKE | 1,645,893 | $39.1M | 17.59% |
| 2 | Beta Bionics Inc. | BBNX | 1,920,125 | $38.2M | 17.16% |
| 3 | BridgeBio Oncology Therapeutics Inc. | BBOT | 3,289,661 | $38.1M | 17.13% |
| 4 | Bicara Therapeutics Inc. | BCAX | 2,204,650 | $34.8M | 15.66% |
| 5 | Nuvation Bio | NUVB | 8,831,089 | $32.7M | 14.69% |
| 6 | Upstream Bio Inc. | UPB | 1,356,293 | $25.5M | 11.47% |
| 7 | ImageneBio, Inc. | IMA | 455,361 | $3.7M | 1.67% |
| 8 | enGene Holdings Inc. | ENGNW | 526,357 | $3.6M | 1.62% |
| 9 | Sana Biotechnology, Inc. | SANA | 843,750 | $3.0M | 1.35% |
| 10 | Alumis Inc. | ALMS | 653,223 | $2.6M | 1.17% |
| 11 | Replimune Group | REPL | 248,672 | $1.0M | 0.47% |
| 12 | enGene Holdings Inc. | ENGNW | 89,702 | $63,438 | 0.03% |